In this episode, we discuss new evidence for cardiovascular outcomes in diabetics based on the LEADER trial (liraglutide) and CANVAS trials (canagliflozin). We also discuss the new FDA warning for canagliflozin regarding amputation risk.
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast","authorlink":""},"src":"https:\/\/traffic.libsyn.com\/secure\/helixtalk\/067_-_DM2017_Part2.mp3?dest-id=187168","thumb":{"src":"https:\/\/lystnimg.b-cdn.net\/podcastsnw-202310\/51d8ce-5810-087d-300941_800.png"},"title":"067 - Diabetes: does it cost a \u201cheart\u201d and a leg?","link":"javascript:;","id":"item-685438"}]
